Research Update: Analysis on the current quality standards of Chinese – newvita

We Accept All Major Credit Cards & Paypal

Research Update: Analysis on the current quality standards of Chinese materia Medica used in COVID-19 prevention and treatment

Posted by Dr. Luke on

2020 Oct; 160: 105074.
Published online 2020 Jul 9. doi: 10.1016/j.phrs.2020.105074
PMCID: PMC7347313
PMID: 32653649

Graphical abstract

Keywords: Coronavirus disease 2019, Traditional Chinese medicine, Chinese Materia Medica, Quality standards, ISO/TC 249



Traditional Chinese medicine (TCM) has fully engaged and played an essential role in the prevention and treatment of Coronavirus Disease 2019 (COVID-19). This study compares relevant standards on high-frequent Chinese Materia Medicia (CMM) used in this pandemic aiming at reaching a global consensus and ensuring the use of Chinese medicines safely.


141 representative Chinese formulas and Chinese Patent Medicines from the National Protocol and the most of Provincial Protocols for controlling COVID-19 in China have been collected to statistical analyze the composition and characteristics of CMM. Among them, the domestic and international standards of 47 varieties with the frequency usage over 10 times were selected to compare their quality requirements in the mainstream pharmacopoeias and international standards.


The quality requirements of used CMM for fighting COVID-19 on the terms of overall quality control, marker compounds, and safety indicators showed different patterns in these mainstream pharmacopoeias and international standards. The uniformed and scientific quality standards of CMM were urgently needed to promote global acceptation and trade.


These findings will provide evidence for building unified quality and safety standards that can adapt to the characteristics of CMM and promote international trade, and also will be stated that it is of the highest priority for ISO/TC 249 to formulate high-quality standards that consolidate international consensus to ensure quality and safety of the urgently needed CMM.

1. Introduction

Since the outbreak of Coronavirus Disease 2019 (COVID-19) in China in December 2019, in the absence of a specific Western medicine and vaccine, traditional Chinese medicine (TCM) has played an essential role in COVID-19 prevention and treatment in China. From the third trial version onwards of the seventh edition of Diagnosis and Treatment Protocol for COVID-19 (the National Protocol) issued by the General Office of National Health Commission of China and State Administration of TCM, it has been clarified that COVID-19 falls under the category of "pestilences" in TCM. In accordance with the treatment principle of abidance by individuality, locality and seasons and the National Protocol, China's provinces (autonomous regions and municipalities directly under the Central Government) have formulated and released regional-specific TCM treatment and prevention protocols based on regional characteristics (the Provincial Protocol) [,]. With the full play of the characteristics and advantages of TCM, integrated Chinese and Western treatment has achieved satisfactory result [, , , ].

It is widely acknowledged that TCM plays an important role and is one of the merits in the epidemic prevention and control. A press conference held on the effectiveness of TCM in the treatment of COVID-19 cases in Wuhan reported that clinical observation showed that TCM has proven to be effective in the treatment of over 90 % of all confirmed COVID-19 cases on the Chinese mainland, said a TCM official on March 24, 2020. Among these confirmed cases, 74,187 were given TCM products, accounting for 91.5 % of the total []. It was found that TCM helped to relieve the symptoms, reduce the progression from mild to severe and critical, increase recovery rate, decrease mortality rate, and bring the convalescent to normal body functions [, , , ]. Meanwhile, we noticed that China has adopted the methods of integrating traditional Chinese medicine with western medicine which led to a better outcome of this pandemic.

As Chinese Materia Medica (CMM) played a key role in this pandemic, its standards on quality and safety are attracting more attentions from the public. ISO/TC 249 has accumulated rich experience in developing international standards on CMM and relevant monographs have been recorded in national pharmacopoeias which enable CMM to be used globally. In this study, we aimed at analyzing the above-mentioned standards on CMM to recognize the current challenges in the process of their development.

2. Materials and methods

141 representative formulas and Chinese Patent Medicines from the National Protocol (the third trial version onwards of the seventh edition) and the main 25 Provincial Protocol of China [,] were selected and the usage frequency of each herbal medicine was counted. There are 47 varieties of CMM with the usage frequency over 10 times. Their botanical origins, morphological identification, and qualitative identification, quantification of marker compounds, heavy metals and residual pesticides in the following mainstream pharmacopoeias and international standards were summarized and compared,

Chinese Pharmacopoeia (ChP),

The Japanese Pharmacopoeia (JP),

The Korean Pharmacopoeia (KP),

European Pharmacopoeia (EP),

U.S. Pharmacopoeia (USP),

U.S. Pharmacopoeia-Herbal Medicine Compendium (USP-HMC),

WHO monographs on selected medicinal plants, and

ISO standards.

3. Results and discussions

3.1. Statistical analysis of Chinese Materia Medica used in the Chinese formulas and Chinese Patent Medicines for COVID-19 prevention and treatment

There are 231 varieties of CMM used in the 141 representative formulas and Chinese Patent Medicines, covering botanical medicines, mineral medicines, and animal medicines. Among them, botanical medicines account for 83.55 % (193 varieties), mineral medicines for 8.66 % (20 varieties) and animal medicines for 7.79 % (18 varieties), and the number varieties types between mineral medicines and animal medicines is close to each other. The CMM used in the formulas over 10 times account for 20.35 % (47 varieties), including 45 varieties of botanical medicines, one variety of mineral medicine, and one variety of animal medicine (Table 1 ).

Table 1

The Chinese Materia Medica of 141 representative formulas and Chinese Patent Medicines for COVID-19 prevention and treatment (usage frequency≥10 times).

Rank Botanical/mineral/animal Name Pharmaceutical Name Chinese Name English Name Frequency of use (times)
1 Glycyrrhiza uralensis Root and Rhizome/ Glycyrrhiza inflata Root and Rhizome/ Glycyrrhiza glabra Root and Rhizome Glycyrrhizae Radix et Rhizoma 甘草 Licorice Root 66
2 Prunus armeniaca var. ansu Seed/ Prunus sibirica Seed/ Prunus mandshurica Seed/ Prunus armeniaca Seed Armeniacae Semen Amarum 苦杏仁 Bitter Apricot Seed 43
3 Gypsum Gypsum Fibrosum 石膏 Plaster 36
4 Scutellaria baicalensis Root Scutellariae Radix 黄芩 Baical Skullcap Root 35
5 Forsythia suspensa Fruit Forsythiae Fructus 连翘 Weeping Forsythia Capsule 34
6 Poria cocos Sclerotium Poria 茯苓 Indian Bread 33
7 Ephedra sinica Stem/ Ephedra intermedia Stem/ Ephedra equisetina Stem Ephedrae Herba 麻黄 Ephedra 33
8 Citrus reticulata Pericarp Citri Reticulatae Pericarpium 陈皮 Dried Tangerine Peel 31
9 Pogostemon cablin Herb Pogostemonis Herba 广藿香 Cablin Patchouli Herb 31
10 Lonicera japonica Flower Lonicerae Japonicae Flos 金银花 Japanese Honeysuckle Flower 30
11 Platycodon grandiflorum Root Platycodonis Radix 桔梗 Platycodon Root 28
12 Pinellia ternata Tuber Pinelliae Rhizoma 半夏 Pinellia Tuber 28
13 Magnolia officinalis Bark/ Magnolia officinalis var. biloba Bark Magnoliae Officinalis Cortex 厚朴 Officinal Magnolia Bark 26
14 Ophiopogon japonicus Root Tuber Ophiopogonis Radix 麦冬 Dwarf Lilyturf Tuber 23
15 Atractylodes macrocephala Rhizome Atractylodis Macrocephalae Rhizoma 白术 Largehead atractylodes Rhizome 23
16 Atractylodes chinense Rhizome/ Atractylodes lancea Rhizome Atractylodis Rhizoma 苍术 Atractylodes Rhizome 22
17 Rheum palmatum Root and Rhizome/ Rheum tanguticum Root and Rhizome/ Rheum officinale Root and Rhizome Rhei Radix et Rhizoma 大黄 Rhurbarb 21
18 Astragalus membranaceus var. mongholicus Root/ Astragalus membranaceus Root Astragli Radix 黄芪 Milkvetch Root 20
19 Phragmites communis Trin. Rhizome Phragmitis Rhizoma 芦根 Reed Rhizome/ Rhizome Phragmitis 19
20 Panax ginseng Root Ginseng Radix et Rhizoma 人参 Ginseng 19
21 Descurainia sophia Seed/ Lepidium apetalum Seed Descurainiae Semen/ Lepidii Semen 葶苈子 Pepperweed Seed/ Tansymustard Seed 17
22 Schisandra chinensis Fruit Schisandrae Chinensis Fructus 五味子 Chinese Magnoliavine Fruit 17
23 Anemarrhena asphodeloides Rhizome Anemarrhenae Rhizoma 知母 Common Anemarrhena Rhizome 15
24 Paeonia lactiflora Root/ Paeonia veitchii Root Paeoniae Radix Rubra 赤芍 Red Peony Root 15
25 Trichosanthes kirilowii Seed/ Trichosanthes rosthornii Seed Trichosanthis Semen 瓜蒌子 Snakegound Seed 15
26 Bupleurum chinense Root/ Bupleurum scorzonerifolium Root Bupleuri Radix 柴胡 Chinese Thorowrax Root 14
27 Prunus persica Seed/ Prunus davidiana Seed Persicae Semen 桃仁 Peach Seed 14
28 Rehmannia glutinosa Root Rehmanniae Radix 地黄 Rehmannia Root 14
29 Pseudostellaria heterophylla Root Pseudostellariae Radix 太子参 Heterophylly Falsestarwort Root 13
30 Morus alba Bark Mori Cortex 桑白皮 Mulberry Root Bark 13
31 Amomum tsao-ko Fruit Tsaoko Fructus 草果 Caoguo 13
32 Areca catechu Seed Arecae Semen 槟榔 Areca Seed 13
33 Coix lacrymajobi var. mayuen Kernel Coicis Semen 薏苡仁 Coix Seed 13
34 Artemisia Annua Herb Artemisiae Annuae Herba 青蒿 Sweet Wormwood Herb 12
35 Cornus officinalis Sarcocarp Corni Fructus 山茱萸 Asiatic Cornelian Cherry Fruit 12
36 Perilla frutescens Leaf Perillae Folium 紫苏叶 Perilla Leaf 11
37 Processed Aconitum carmichaeli Daughter Root Aconiti Lateralis Radix Praeparata 附子 Prepared Common Monkshood Daughter Root 11
38 Codonopsis pilosula Root/ Codonopsis pilosula var. modesta Root/ Codonopsis tangshen Root Codonopsis Radix 党参 Tangshen 10
39 Lophatherum gracile Stem and Leaf Lophatheri Herba 淡竹叶 Lophatherum Herb 10
40 Saposhnikovia divaricata Root Saposhnikoviae Radix 防风 Divaricate Saposhnikovia Root 10
41 Zingiber officinale Rhizome Zingiberis Rhizoma 生姜 Zingiber 10
42 Picrorhiza scrophulariiflora Rhizome Picrorhizae Rhizoma 胡黄连 Figwortflower Picrohiza Rhizome 10
43 Gardenia jasminoides Fruit Gardeniae Fructus 栀子 Cape Jasmine Fruit 10
44 Fritillaria thunbergii Bulb Fritillariae Thunbergii Bulbus 浙贝母 Thunberg Fritillary Bulb 10
45 Mentha haplocalyx Herb Menthae Haplocalycis Herb 薄荷 Peppermint 10
46 Notopterygium incisum Rhizome and Root/ Notopterygium franchetii Rhizome and Root Notopteryqii Rhizoma et Radix 羌活 Incised Notopterygium Rhizome or Root 10
47 Bubalus bubalis Cornu Bubali Cornu 水牛角 Buffalo Horn 10

The commonly used CMM are Glycyrrhizae Radix et Rhizoma (gān căo), Armeniacae Semen Amarum (xìng rén), Gypsum Fibrosum (shí gāo), Scutellariae Radix (huáng qín), Forsythiae Fructus (lián qiào), Ephedrae Herba (má huáng), Lonicerae Japonicae Flos (jīn yín huā), Atractylodis Macrocephalae Rhizoma (bái zhú), etc. The formulas for COVID-19 have been put forward combined with TCM theory and clinical practice, and the commonly used pairs of CMM are Ephedrae Herba-Armeniacae Semen Amarum (má huáng-xìng rén), Ephedrae Herba-Gypsum Fibrosum (má huáng-shí gāo), Agastachis Herba-Magnoliae Officinalis Cortex (huò xiāng-hòu pò), Lonicerae Japonicae Flos-Forsythiae Fructus (jīn yín huā-lián qiào), Lepidii Semen-Gypsum Fibrosum (tíng lì zĭ-shí gāo).

3.2. Current situations of quality standards for CMM and comparative analysis

The quality standards of CMM is a key technical link for CMM to break the barriers of international trade and gain access to international markets. Under the framework of the globalization of CMM, with the ultimate goal to gain access to international markets, it is indispensable to promote internationalization of CMM by formulating a scientific, advanced and applicable system for quality standards with international recognition to effectively ensure efficacy and safety of CMM.

The current quality standards of the above selected 47 varieties of CMM in the mainstream pharmacopoeias and international standards are shown as follows.


3.2.1. Situation of the standards Situation of standards collected by the mainstream pharmacopoeias [, , , , , ]

All varieties of used CMM have corresponding quality standards in ChP, with more than 85 % collected in JP and KP but with fewer description in EP and USP/ USP-HMC for 31.91 % and 25.53 %, respectively (Table 2 ).

Table 2

The status of the collection of standards for 47 varieties of Chinese Materia Medica (usage frequency ≥ 10 times) in the mainstream pharmacopoeias and international organizations.

Rank Pharmaceutical Name ChP JP KP EP USP ISO WHO
1 Glycyrrhizae Radix et Rhizoma a
2 Armeniacae Semen Amarum
3 Gypsum Fibrosum
4 Scutellariae Radix
5 Forsythiae Fructus
6 Poria
7 Ephedrae Herba
8 Citri Reticulatae Pericarpium
9 Pogostemonis Herba
10 Lonicerae Japonicae Flos
11 Platycodonis Radix a
12 Pinelliae Rhizoma a
13 Magnoliae Officinalis Cortex
14 Ophiopogonis Radix
15 Atractylodis Macrocephalae Rhizoma
16 Atractylodis Rhizoma
17 Rhei Radix et Rhizoma a
18 Astragli Radix
19 Phragmitis Rhizoma
20 Ginseng Radix et Rhizoma a
21 Descurainiae Semen/ Lepidii Semen
22 Schisandrae Chinensis Fructus
23 Anemarrhenae Rhizoma
24 Paeoniae Radix Rubra
25 Trichosanthis Semen
26 Bupleuri Radix
27 Persicae Semen
28 Rehmanniae Radix a
29 Pseudostellariae Radix
30 Mori Cortex
31 Tsaoko Fructus
32 Arecae Semen
33 Coicis Semen
34 Artemisiae Annuae Herba
35 Corni Fructus
36 Perillae Folium
37 Aconiti Lateralis Radix Praeparata
38 Codonopsis Radix
39 Lophatheri Herba
40 Saposhnikoviae Radix a
41 Zingiberis Rhizoma
42 Picrorhizae Rhizoma a
43 Gardeniae Fructus
44 Fritillariae Thunbergii Bulbus
45 Menthae Haplocalycis Herb
46 Notopteryqii Rhizoma et Radix
47 Bubali Cornu
Coverage ratio of standards for the 47 varieties (%) 100.00 87.23 85.11 31.91 25.53 30.04 29.79
aThese CMM as new work item proposal (NWIP) have been submitted into ISO/TC 249 platform, and they have not been officially approved as new projects. Situation of standards collected by WHO monographs and ISO [,]

There are 14 varieties included in WHO monographs on selected medicinal plants, and 16 varieties included in ISO international standards. For ISO standards, 2 varieties of CMM, Lonicerae Japonicae Flos and Scutellariae Radix have been officially published, and 14 varieties are under development stage (Table 3 ).

Table 3

The list of 47 varieties of Chinese Materia Medica with usage frequency over10 times included by ISO/TC 249 platform.

No. English Name Chinese Name Sponsor Countries Current Stage
1 ISO 21317:2019 Traditional Chinese medicine—Lonicera japonica flower 中医药—金银花 China Published
2 ISO 22988:2020Traditional Chinese medicine—Astragalus mongholicus root 中医药—蒙古黄芪 China
3 ISO 23,962 Traditional Chinese Medicine—Processed Aconitum carmichaeliilateral root 中医药—附子 China Draft international Standard (DIS)
4 ISO 22,585 Traditional Chinese Medicine—Codonopisispilosula root 中医药—党参 China Working Draft
5 ISO 23,965 Traditional Chinese Medicine—Bupleurum chinense and Bupleurum scorzonrifoliumroot 中医药—柴胡 China
6 ISO 4564 Traditional Chinese Medicine—Scutellariabaicalensis Georgi root 中医药—黄芩 China
7 Traditional Chinese Medicine—Panax ginseng root 中医药—人参 China New Work Item Proposal (NWIP)
8 Traditional Chinese medicine—Glycyrrhiza uralensis root and rhizome 中医药—甘草 China
9 Traditional Chinese medicine—Pinelliaternata tuber 中医药—半夏 China
10 Traditional Chinese medicine—Rehmanniaglutinosa root 中医药—地黄 China
11 Traditional Chinese Medicine—Arecae Semen 中医药—槟榔 China
12 Traditional Chinese Medicine—Saposhnikoviadivaricata root and rhizome 中医药—防风 China
13 Traditional Chinese Medicine— Platycodon grandiflorum root 中医药—桔梗 Republic of Korea
14 Traditional Chinese medicine— Schisandra chinensis fruit 中医药—五味子 Republic of Korea
15 Traditional Chinese Medicine —Rheum root and rhizome 中医药—大黄 Germany
16 Traditional Chinese Medicine—Coptis rhizome 中医药—黄连 Canada Situation of standards collected by the mainstream pharmacopoeias and international standards

The standard of Scutellariae Radix is the only CMM that has been recorded in ChP, JP, KP, EP, USP, ISO and WHO monograph. The standards of Glycyrrhizae Radix et Rhizoma, Ginseng Radix et Rhizoma, and Schisandrae Chinensis Fructus have been recorded in ChP, JP, KP, EP, USP and WHO other than ISO.


3.2.2. Comparative analysis of the standards and current challenges

Based on the characteristics of CMM, the standards of the mainstream pharmacopoeias and international standards mainly focus on the safety issues of CMM, such as botanical origins, morphological identification, and qualitative identification, quantification of marker compounds, heavy metals and residual pesticides [, , , , , , , ]. However, the mainstream pharmacopoeias and international standards have different emphases on standards in terms of overall quality control of CMM, selection of marker compounds, safety issues and others. Taking Scutellariae Radix as an example, the comparative analysis of the standards among the mainstream pharmacopoeias, ISO and other international standards is as follows (Table 4 ):

  • 1)

    Apart from the basic contents such as botanical origins, morphological features, microscopic characteristics, qualitative identification, purity test, assay, and storage, etc. of the CMM, ChP has included other factors including nature, flavor and meridian distribution, functions and indications, usage and dosage; while ISO and USP standards elaborate on packaging, transportation and labeling.

  • 2)

    Purity test includes moisture and total ash contents, but with differences in limit values of each standard.

  • 3)

    The regulations and requirements on safety indicators such as heavy metals and residual pesticides showed a different pattern in these mainstream pharmacopoeias and international standards.

  • 4)

    The main differences of the standards are the gaps in the selection of marker compounds and limitation regulation. The single marker compound of baicalin is used for quantitative analysis in ChP, EP, JP, ISO, and WHO standards, while apart from baicalin, multi-marker compounds are referred in KP and USP.


Table 4

The comparative analysis of quality standards for Scutellariae Radix in the standards of the mainstream pharmacopoeias, WHO and ISO.

Items ChP, 2015 JP, 17th KP, 11th EP, 9.0 USP-HMC WHO monograph ISO
Identification Microscopic
TLC Reference crude drug; Baicalin; Baicalein; Wogonin Reference crude drug; Baicalin Reference crude drug Baicalin;
Reference crude drug; Baicalin; Baicalein Baicalin
Loss on drying ≤10.0 % ≤12.0 % ≤15.0 % ≤12.0 % ≤12.0 % ≤12.0 % ≤15.0 %
Total ash ≤6.0 % ≤5.0 % ≤6.0 % ≤6.0 % ≤6.0 % ≤6.0 % ≤6.0 %
Acid-insoluble Ash ≤1.0 % ≤2.0 % ≤1.0 % ≤1.0 %
Ethanol-soluble extractives ≥40.0 % ≥24.0 % ≥18.0 % ≥15.0 % ≥26.0 %
Water-soluble extractives ≥28.0 % ≥40.0 %
Assay Baicalin: ≥9.0 % Baicalin: ≥10.0 % ≥10.0 % (total of Baicalin, baicalein and wogonin) Baicalin: ≥9.0 % ≥11.0 % (total of Baicalin and wogonin-7-O-glucuronide);
≥3.50 % (total of Baicalin and wogonin)
Baicalin: ≥9.0 % Baicalin: ≥8.0 %
Heavy metals
Pesticide residuals
Sulfur dioxide ≤ 150 ppm ≤ 30 ppm

3.3. Necessity of formulating international standards for CMM and characteristics of ISO/TC 249 international standards for CMM

Pharmacopoeias are the important technical code for quality and safety management of medicines in different countries and are the legal norms and evidence for the entry to the pharmaceutical markets. Through the coordination of pharmacopoeia standards, global free trade of high-quality pharmaceutical products can be promoted. Although TCM has been widely promoted globally, due to the inherent characteristics of CMM and the sparks between traditional and modern evaluation systems, CMM has been variously identified in different countries and has difficulties in international registration [, , ]. The phenomena mainly result from the barriers to connect the quality standards for CMM with the mainstream markets in Europe and US, and restrictions of medical regulations and policies in different countries/regions. Major differences were identified in the classification of CMM and its products, market entry pathways, requirements of compliance with Good Manufacturing Practices; and level of evidence to demonstrate safety and efficacy based on historical use, non-clinical and clinical studies. Variations in the evaluation standards adopted by regulatory authorities pose a number of barriers and opportunities for the internationalization of TCM products [].

It is not easy to fully understand the properties and curative effects of CMMs under the current knowledge and methodologies we have had. On the other hand, some western countries still have stipulated strict regulations on the registration of Chinese medicines before they could be sold. Such is the dilemma we meet: trying to follow the modern evidence-based approaches for registration while retaining unique characteristics of TCM. It can be highly desirable to develop ISO standards on each herbal medicine to serve as a reference during those registration processes.

Although the pharmacopoeias of different countries have a certain global impact, due to the disparities in initial motivations and target groups of the pharmacopoeias, it is difficult to apply to the standard of a specific country as supporting evidence for arbitration in international arbitration once a trade dispute occurs. Furthermore, due to the limited varieties of CMM included in the pharmacopoeias of Europe, US and other countries, or the disputes in the selection of the marker compounds, it is difficult for the existing standards to adapt to the needs of international trade of CMM.

Based on consultative and consensus-based processes, ISO/TC249 provides a platform to develop standards which represent global expert opinion across consumers, practitioners, industry, academics from universities, and government. For standards on CMMs, there are still large disparities in the levels of requirements between a range of countries and their national pharmacopoeias. Therefore, ISO/TC249 can serve the purpose of filling the gaps and supporting the appropriate use of CMMs. With a focus on the demands for the international market, ISO/TC 249 has been dedicated to filling in the blanks of the universal standards for international trade of CMM, stipulating international standards for CMM, strengthening quality control and safety requirements of CMM, and conducting a large amount of research on the detection of residual pesticides and heavy metals, etc.. In order to complete the above tasks in an organized manner, ISO/TC 249 have formulated and released ‘ISO/TR 23975: 2019 Traditional Chinese medicine–Priority list of single herbal medicines for developing standards’ [] from the needs of international trade, the status of pharmacopoeias in different countries, the degree of safety issues of CMM, the status of the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES) collection, and the consensus of experts in all countries. It aims at establishing unified quality standards that can adapt to the characteristics of CMM, ensure safety and effectiveness, and are applicable to international trade. With the new challenges and suggestions that COVID-19 brings us, the commonly used CMM in COVID-19 prevention and treatment need to be prioritized more appropriate, and the international standards should be published in a timely manner. With the endorsement of ISO international standards, TCM should play its role in the prevention and treatment of major infectious diseases worldwide. By comparative studies, the data has shown that among the 47 varieties of CMM with a usage frequency over 10 times for fighting COVID-19, only 22 varieties (46.81 %) are currently included in ISO/TR 23975. In other words, there is much to be engaged for ISO international standards in this field.

3.4. Further thoughts on international standards of ISO/TC 249 in responding to major emergencies of public health

The outbreak of COVID-19 reminds us that in dealing with major emergencies of global public health, it is of great importance to transcend the borders and build a global community of shared wellbeing now. The understanding and diagnosis and treatments of TCM for diseases and health care, over hundreds of years’ application supports the efficiency and safety of Chinese medicines, and its contribution to the wellbeing should be shared by the mankind. It is an important mission of ISO/TC 249 to promote TCM contribution to the wellbeing of the mankind by stipulating international standards of high quality.

CMM have the characteristics of diversity and complexity of ingredients, which is difficult to comprehensively evaluate by the quality control and assessment mode of single ingredient of modern chemical medicines. For the key scientific problems urgently needed to be solved in the internationalization and standardization of CMM, with the focus on the methodology for comprehensive characterization of the overall composition of CMM and the establishment of quality evaluation system, the demarcation of toxic CMM between effectiveness and safety, and the formulation of the limitation range of effect-toxic ingredients [, , ], we need to integrate the concepts of stipulating standards of the mainstream pharmacopoeias and ISO standards, etc., and to establish a scientific quality standard system that can adapt to the characteristics of CMM and can be generally recognized by the international community. Based on the experience of fighting COVID-19, it is urgent for ISO/TC 249 to formulate high-quality standards that consolidate international consensus to ensure the quality and safety of the urgently needed CMM.

4. Conclusions

In this study, the characteristics of used CMM for prevention and treatment of COVID-19, and the quality requirements of 47 main varieties of CMM in mainstream pharmacopoeias and international standards were comprehensively analyzed and compared. These findings provide evidence for developing harmonized standards which can be relied on to guarantee the safety and quality of CMM. This study also stated that it is of the highest priority for ISO/TC 249 to formulate high-quality standards that can consolidate global consensus and contain the characteristics of CMM at most.

Declaration of Competing Interest

The authors declared that there is no conflict of interest.


This work was supported Three-year action plan for the development of TCM in Shanghai-Construction on international standardization of TCM in ISO (No. ZY (2018-2020)-GJHZ-1003); the Science and Technology Development Fund, Macao SAR (File no. 0061/2019/AGJ, 0027/2017/AMJ and 062/2017/A2); and Special project of Technical Barriers to Trade in Shanghai (No. 19TBT019).


1. General Office of the National Health and Health Commission, Office of the State Administration of Traditional Chinese Medicine. Notice on Issuing a New Coronary Virus Pneumonia Diagnosis and Treatment guidelines (Trial Version 7) [EB/OL]., (accessed Mar 4, 2020, in Chinese).
2. Jiangsu Research Center for Chinese Medicine Development . 2020. Trend Book of Diagnosis and Treatment Protocol of Traditional Chinese Medicine for COVID-19. [EB/OL]. (accessed Feb 19, 2020, in Chinese) []
3. Chan K.W., Wong V.T., Tang S.C.W. COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese–Western Medicine for the Management of 2019 Novel Coronavirus Disease. Am. J. Chin. Med. 2020;43:737–762. [PubMed] []
4. Ni L., Zhou L., Zhou M., Zhao J., Wang D.W. Combination of western medicine and chinese traditional patent medicine in treating a family case of COVID-19 in Wuhan. Front. Med. 2020;14:210–214. [PMC free article] [PubMed] []
5. Liu M., Gao Y., Yuan Y., Yang K., Shi S., Zhang J., Tian J. Efficacy and Safety of Integrated Traditional Chinese and Western Medicine for Corona Virus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis. Pharmacol. Res. 2020;158 [PMC free article] [PubMed] []
6. Ren J.L., Zhang A.H., Wang X.J. Traditional Chinese medicine for COVID-19 treatment. Pharmacol. Res. 2020;155 [PMC free article] [PubMed] []
7. The State Council Information Office, The People’s Republic of China, TCM treatment effective on over 90% of COVID-19 patients on China’s mainland: Official [EB/OL], (accessed March 24, 2020, in English).
8. Hu K., Guan W.J., Bi Y., Zhang W., Li L., Zhang B., Liu Q., Song Y., Li X., Duan Z., Zheng Q., Yang Z., Liang J., Han M., Ruan L., Wu C., Zhang Y., Jia Z.H., Zhong N.S. Efficacy and safety of Lianhuaqingwen Capsules, a repurposed chinese Herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial. Phytomedicine. 2020:153242. doi: 10.1016/j.phymed.2020.153242. [PMC free article] [PubMed] [CrossRef] []
9. Zhang D., Zhang B., J.T Lv, Sa R.N., Zhang X.M., Lin Z.J. The clinical benefits of chinese patent medicines against COVID-19 based on current evidence. Pharmacol. Res. 2020;157:104882. [PMC free article] [PubMed] []
10. Luo E., Zhang D., Luo H., Liu B., Zhao K., Zhao Y., Bian Y., Wang Y. Treatment efficacy analysis of traditional chinese medicine for novel coronavirus pneumonia (COVID-19): an empirical study from Wuhan, Hubei Province. China, Chin. Med. 2020;15:34. [PMC free article] [PubMed] []
11. Yang Y., Islam M.S., Wang J., Li Y., Chen X. Traditional chinese medicine in the treatment of patients infected with 2019-New coronavirus (SARS-CoV-2): a review and perspective. Int. J. Biol. Sci. 2020;16:1708–1717. [PMC free article] [PubMed] []
12. National Pharmacopoeia Committee . Chemical Industry Press; Beijing: 2015. Chinese Pharmacopoeia, Part 1. []
13. Japanese Pharmacopoeia Convention . 17th ed. Society of Japanese Pharmacopoeia; Tokyo: 2016. Japanese Pharmacopoeia. []
14. Korea food and drug administration . 10th ed. Yakup Daily, Seoul; 2002. The Korean Herbal Pharmacopoeia. []
15. European Pharmacopoeia. 9th ed. 2016. The European pharmacopoeia directorate for the quality of medicines & HealthCare of the council of Europe (EDQM) []
16. The United States Pharmacopieial Convention . 2016. The United States Pharmacopeia (USP40-NF35), New York. []
17. The United States Pharmacopieial Convention . 2015. United States Pharmacopoeia-Herbal Medicines Compendium 1.0. []
18. World Health Organization (WHO): Essential medicines and health products-WHO monographs on Selected Medicinal Plants (Vol.1-Vol.3),
19. The International Organization for Standardization/ Technical Committee of Traditional Chinese medicine (ISO/TC 249):
20. Lin A.X., Chan G., Hu Y., Ouyang D., Ung C.O.L., Shi L., Hu H. Internationalization of traditional Chinese medicine: current international market, internationalization challenges and prospective suggestions. Chin. Med. 2018;13(9):1–6. [PMC free article] [PubMed] []
21. Knoess W., Wiesner J. The globalization of Traditional Medicine: perspectives related to the European Union regulatory environment. Engineering. 2019;5:22–31. []
22. Li J., Zhu J., Hu H., Harnett J.E., Lei C.I., Chau K.Y., Chan G., Ung C.O.L. Internationalization of Traditional/Complementary Medicine products: market entry as medicine. Chin. Med. 2018;13(50):1–15. [PMC free article] [PubMed] []
23. ISO/TR 23975 . 2019. Traditional Chinese Medicine–Priority List of Single Herbal Medicines for Developing Standards. []
24. Wu W.Y., Yang W.Z., Hou J.J., Guo D.A. Current status and future perspective in the globalization of traditional Chinese medicines. World J. Tradit. Chin. Med. 2015;1(1):1–4. []
25. Gao Y., Liang A., Fan X., Hu L., Hao F., Li Y. Safety research in traditional Chinese medicine: methods, applications, and outlook. Engineering. 2019;5:76–82. []
26. Zhang T., Bai G., Han Y., Xu J., Gong S., Li Y., Zhang H., Liu C. The method of quality marker research and quality evaluation of traditional Chinese medicine based on drug properties and effect characteristics. Phytomedicine. 2018;15:204–211. [PubMed] []



This article is cited from Pharmacol Res., Oct 2020. doi: 10.1016/j.phrs.2020.105074

The information mentioned in this article is for education and information only. It is not intended to diagnose, treat, cure, or prevent any disease and do not replace medical advice. Advice on treatment or care of an individual patient should be obtained through consultation with a physician or trained health care practitioner who has examined that patient or is familiar with that patient's medical history.

This information and advice published or made available through this website are not intended to replace the services of a physician or a health care professional acting under a physician’s supervision, nor does it constitute a doctor-patient relationship. Each individual’s treatment and/or results may vary based upon the circumstances, the patients’ specific situation, as well as the health care provider’s medical judgment and only after further discussion of the patient’s specific situation, goals, risks, and benefits, and other relevant medical discussions.

Statements made by any person(s) in this article are not intended to substitute for this discussion or evaluation or as a guarantee as to outcomes. Examples of treatment outcomes in this article are not intended to convey and warranty, either express or implied, as to outcomes, promises, or benefits from treatment. Whether to accept any treatment by a patient should be assessed by the patient as to the risks and benefits of such procedures and only after consultation with a health care professional.

The use of this article constitutes acknowledgment and acceptance of these limitations and disclaimers. Further dissemination of this information in this site is prohibited without express written approval from newvita.

Share this post

← Older Post Newer Post →